Keyword: Centers for Disease Control and Prevention
Top U.S. officials guiding the pandemic response are dealing with a COVID-19 outbreak in the country's most high-profile workplace—the White House.
With its chances already murky after a series of small studies, VA researchers now say hydroxychloroquine flopped another small-scale study.
Several Big Pharma companies have either prohibited travel to and from China or postponed business meetings in affected areas.
With HIV rates in the U.S. holding steady, health officials are looking to drugmakers to help drive down infections. Now, Gilead is ready to chip in.
Here is some other vaccine news of note for the week.
Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.
After a horrible flu season last year, more people have gotten vaccinations so far this year, according to the CDC.
Experts urged the U.S. to allow CDC staff to return to the field, though WHO's director-general insists financial and other support should suffice.
GlaxoSmithKline is working to boost its supply of shingles vaccine Shingrix, but in the meantime, a shortage will last until next year.
The government is riled up about drug prices and promising to drive them down, but a CMS report shows retail drug spending grew just 0.4% last year.